[Pharmacological considerations in the economic evaluation of glycopeptides].
García-Quetglas
E
E
Servicio de Farmacología Clínica, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra.
Sádaba
B
B
Honorato
J
J
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics* / Q000494:pharmacology*; D019072:Antibiotic Prophylaxis / Q000191:economics*; D001170:Arthritis, Infectious / Q000188:drug therapy; D016470:Bacteremia / Q000188:drug therapy; D001424:Bacterial Infections / Q000188:drug therapy; D003365:Costs and Cost Analysis; D016903:Drug Monitoring / Q000191:economics; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D006801:Humans; D010019:Osteomyelitis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D017334:Teicoplanin / Q000008:administration & dosage / Q000191:economics* / Q000494:pharmacology*; D013997:Time Factors; D014640:Vancomycin / Q000008:administration & dosage / Q000191:economics* / Q000494:pharmacology*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin